Pressure BioSciences (NASDAQ:PBIO) was featured on BiotechStockTrader.com on Tuesday, in an article that said the company's stock was undervalued.
The article detailed the company's "game-changing" pressure cycling
technology (PCT), which uses alternating cycles of hydrostatic pressure
to safely and easily control the actions of molecules in the body.
To access the BiotechStockTrader article, please click on this link: http://biotechstocktrader.com/pressure-biosciences-pbio-a-game-changing-technology-platform-361/
Earlier this month, Pressure BioSciences
announced that the Henry C. Lee (HCL) Institute of Forensic Sciences
will evaluate the use of the company's PCT platform for the extraction
of DNA and other biomolecules in a number of forensic areas.
The news follows an earlier collaboration announced in January with
the Florida International University to use the company's PCT platform
to improve rape case DNA testing with a new procedure to selectively
extract male DNA from mixtures of male and female cells.
However, the HCL Institute, which is considered one of the leading
forensic teaching facilities in the world, said it will evaluate Pressure BioSciences'
technology for the extraction of DNA from difficult-to-analyze samples
such as bone, hair, plant tissue, pollen and finger nails - broadening
the applications in the forensic field.
All of these samples can be important in a crime scene, cold case or
archeological investigation, but current methods to prepare difficult
forensic samples are often inadequate or unavailable, the company said.
The company's patented PCT platform uses rapid and repeating cycles
of hydrostatic pressure at controlled temperatures to extract cell
components in the preparation of a biological sample, such as DNA, RNA,
and proteins from humans, animals and plants, for further study.
The applications of the company's PCT-based products are endless -
from the key $2 billion target market of mass spectrometry, an
analytical technique used to determine the characteristics of molecules,
to biomarker discovery, forensics and counter-bioterrorism, among other
uses.
In addition to traditional crime scene samples, the HCL Institute,
based at the University of New Haven, will also test the PCT platform
for detection of counterfeit foods, which may adulterate important food
products such as rice and tea.
Since Pressure BioSciences
began commercial operations in the middle of 2007, it has come a long
way, releasing a number of PCT-based products geared towards the $6
billion sample preparation market, including three pressure-generating
instruments named Barocyclers, a patent-pending sample homogenization
device (The Shredder SG3), five types of single-use processing
containers and six different, application-specific reagent kits.
Already, the company has installed around 200 of its PCT Barocycler
instruments plus required consumables in laboratories. The sample
preparation system has been proven to be safer, more accurate,
reproducible, and much faster than current cell extraction methods -
with up to 48 samples able to be processed from a wide variety of cells
and tissues within minutes.
Indeed, Pressure BioSciences
has been accelerating its commercialization efforts as of late. Earlier
this month, the life sciences company inked another distribution deal
with Netherlands-based life sciences company LA Biosystems BV. In
February, it announced the signing of a co-marketing and selling
agreement with Digilab, and late last year, inked a partnership with IUL
to distribute its PCT product line in Germany and Switzerland.
No comments:
Post a Comment